par John R. Fischer
, Senior Reporter | January 14, 2021
Parexel, which provides regulatory, clinical and consulting services to life science and biopharmaceutical companies, has completed the separation of its Parexel Informatics and Medical Imaging business.
Parexel Informatics will henceforth be known as Calyx.
“The separation enables the Parexel corporate business to strengthen our focus on our core offering — delivery of innovative clinical development solutions that reinforce our patients-first focus and advance world health — all the while providing Calyx the opportunity to prioritize investments in technology development, customer delivery and customer relationships,” Jamie Macdonald, chief executive officer of Parexel, told HCB News.
Numed, a well established company in business since 1975 provides a wide range of service options including time & material service, PM only contracts, full service contracts, labor only contracts & system relocation. Call 800 96 Numed for more info.
The move also better positions both organizations to experience continued long-term growth, according to Macdonald. Calyx will be privately owned by the same group that has owned Parexel since 2017. Chief executive officer Gavin Nichols will head Calyx, which will be headquartered in Nottingham in the U.K. and in Durham, North Carolina. The organization will employ approximately 2,300 employees.
Parexel will be a large customer of Calyx’s Medical Imaging, Clinical Trial Management Systems, Electronic Data Capture, Interactive Response Technology and Regulatory Information Management solutions.
The company previously launched a solution in 2017 called ClinPhone RTSM
, a mobile app designed to enhance clinical trial supply management processes, increase patient safety, and improve the chain of custody record for clinical supplies.
This past December it joined the Decentralized Trials & Research Alliance (DTRA), a new alliance of 50 life sciences and healthcare organizations focused on expanding access to clinical trials by advancing policies, research practices and digital-health technologies in decentralized clinical trials (DCTs). Having conducted its first virtual trial in 2011, it adapted traditional trials to DCT and hybrid models when the pandemic arose to ensure clinical trials continued.
In keeping with its patient-first approach, the company also hired Clare Grace this month as the company’s first chief patient officer.
“Patients are at the heart of everything we do,” said Dr. Sy Pretorius, chief medical and scientific officer at Parexel, in a statement. “Clare’s proven track record of delivering innovative patient and site engagement programs make her the perfect candidate to lead our patient-focused mission. Back to HCB News